Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Ipilimumab

Ipilimumab Reactions 1704, p206 - 2 Jun 2018 Acute inflammatory enterocolitis: case report An 18-year-old man developed acute inflammatory enterocolitis during treatment with ipilimumab for metastatic melanoma [route not stated]. The man, who had been diagnosed with metastatic amelanotic melanoma, was started on first-line therapy with ipilimumab 3 mg/kg plus nivolumab 1 mg/kg every three weeks. He tolerated the treatment well; however, he developed mild hepatitis. The hepatitis was characterised by grade 2 transaminase elevation. After four weeks of methylprednisolone treatment, the hepatitis resolved. After four doses of combination therapy, the metastases decreased and he was started on maintenance therapy with nivolumab 3 mg/kg every second week. After two doses, the underlying disease was progressed. He underwent adjuvant radiotherapy and was started on high-dose ipilimumab 10 mg/kg every three weeks. Five days after the second dose of ipilimumab, he presented with abdominal pain, nausea, loss of appetite, weight loss and vomiting. Therefore, he was hospitalised and was started on IV fluid replacement. CT scans showed a pronounced thickening of the ileum and jejunum walls with contrast enhancement, which was consistent with an inflammatory process. Therefore, he was treated with methylprednisolone along with parenteral fluids and nutrition. In spite of these http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Ipilimumab

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Download PDF
1 page

Ipilimumab

Abstract

Reactions 1704, p206 - 2 Jun 2018 Acute inflammatory enterocolitis: case report An 18-year-old man developed acute inflammatory enterocolitis during treatment with ipilimumab for metastatic melanoma [route not stated]. The man, who had been diagnosed with metastatic amelanotic melanoma, was started on first-line therapy with ipilimumab 3 mg/kg plus nivolumab 1 mg/kg every three weeks. He tolerated the treatment well; however, he developed mild hepatitis. The hepatitis was characterised by...
Loading next page...
1
 
/lp/springer_journal/ipilimumab-kB0WZtL01a

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46849-4
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p206 - 2 Jun 2018 Acute inflammatory enterocolitis: case report An 18-year-old man developed acute inflammatory enterocolitis during treatment with ipilimumab for metastatic melanoma [route not stated]. The man, who had been diagnosed with metastatic amelanotic melanoma, was started on first-line therapy with ipilimumab 3 mg/kg plus nivolumab 1 mg/kg every three weeks. He tolerated the treatment well; however, he developed mild hepatitis. The hepatitis was characterised by grade 2 transaminase elevation. After four weeks of methylprednisolone treatment, the hepatitis resolved. After four doses of combination therapy, the metastases decreased and he was started on maintenance therapy with nivolumab 3 mg/kg every second week. After two doses, the underlying disease was progressed. He underwent adjuvant radiotherapy and was started on high-dose ipilimumab 10 mg/kg every three weeks. Five days after the second dose of ipilimumab, he presented with abdominal pain, nausea, loss of appetite, weight loss and vomiting. Therefore, he was hospitalised and was started on IV fluid replacement. CT scans showed a pronounced thickening of the ileum and jejunum walls with contrast enhancement, which was consistent with an inflammatory process. Therefore, he was treated with methylprednisolone along with parenteral fluids and nutrition. In spite of these

Journal

Reactions Weekly – Springer Journals

Published: Jun 2, 2018

There are no references for this article.